ImmunoGen (NASDAQ:IMGN) : During the past 4 weeks, traders have been relatively bearish on ImmunoGen (NASDAQ:IMGN), hence the stock is down -36.51% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.18% relative to the S&P 500. The 4-week change in the price of the stock is -35.48% and the stock has fallen -0.93% in the past 1 week.
The company shares have dropped -80.86% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $19.43 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $4.33 and the 200 Day Moving Average price is recorded at $7.51.
The stock has recorded a 20-day Moving Average of 8.62% and the 50-Day Moving Average is 35.81%.
ImmunoGen (NASDAQ:IMGN): stock turned positive on Friday. Though the stock opened at $3.14, the bulls momentum made the stock top out at $3.24 level for the day. The stock recorded a low of $3.12 and closed the trading day at $3.2, in the green by 2.56%. The total traded volume for the day was 1,382,972. The stock had closed at $3.12 in the previous days trading.
In an insider trading activity,The officer (Executive Vice President) of Immunogen Inc, Lambert John sold 3,889 shares at $8.22 on February 1, 2016. The Insider selling transaction had a total value worth of $31,968. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.